18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.

Item

http://www.wikidata.org/entity/Q36557319

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

18F-fluorodeoxyglucose (FDG) P ...... n HER2-positive breast cancer.

@ast

18F-fluorodeoxyglucose (FDG) P ...... n HER2-positive breast cancer.

@en

type

Item

label

18F-fluorodeoxyglucose (FDG) P ...... n HER2-positive breast cancer.

@ast

18F-fluorodeoxyglucose (FDG) P ...... n HER2-positive breast cancer.

@en

prefLabel

18F-fluorodeoxyglucose (FDG) P ...... n HER2-positive breast cancer.

@ast

18F-fluorodeoxyglucose (FDG) P ...... n HER2-positive breast cancer.

@en

P1476

18F-fluorodeoxyglucose (FDG) P ...... n HER2-positive breast cancer.

@en

P2093

Daoying Geng

http://www.w3.org/2001/XMLSchema#string

Guangyu Liu

http://www.w3.org/2001/XMLSchema#string

Jingyi Cheng

http://www.w3.org/2001/XMLSchema#string

Jun Zhang

http://www.w3.org/2001/XMLSchema#string

Miao Mo

http://www.w3.org/2001/XMLSchema#string

Xiao Bao

http://www.w3.org/2001/XMLSchema#string

Yingjian Zhang

http://www.w3.org/2001/XMLSchema#string

Yujie Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer

Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients

Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy.

Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATA

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment

Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters.

Prognostic Impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy.

Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.

P304

29388-29395

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.5001

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281514404

http://www.w3.org/2001/XMLSchema#string

P698

26336821

http://www.w3.org/2001/XMLSchema#string

P932

4745734

http://www.w3.org/2001/XMLSchema#string